Rucaparib - Clovis Oncology

Drug Profile

Rucaparib - Clovis Oncology

Alternative Names: AG-014699; AG-14699; CO-338; PF-01367338; PF-1367338; Rubraca; Rucaparib phosphate

Latest Information Update: 01 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research UK
  • Developer Bristol-Myers Squibb; Cancer Research UK; Clovis Oncology; Ohio State University Comprehensive Cancer Center; Roche; UNICANCER; University of California at San Francisco; University of Oklahoma
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Indoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Prostate cancer
  • Phase II Breast cancer; Cervical cancer; Endometrial cancer; Pancreatic cancer; Urogenital cancer
  • Phase I Gynaecological cancer; Solid tumours
  • Suspended Malignant melanoma

Most Recent Events

  • 01 Aug 2018 Clovis Oncology intends to launch Rucaparib in European Union in early 2019
  • 01 Aug 2018 Clovis oncology plans a phase II trial of rucaparib in combination with nivolumab in patients with relapsed, BRCA wild-type ovarian cancer and locally advanced or metastatic bladder carcinoma who are ineligible for treatment with cisplatin (Combination therapy, Late-stage disease) in the second half of 2018
  • 12 Jul 2018 Phase-I clinical trials in Endometrial, Ovarian, Fallopian tube, Peritoneal cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO) (NCT03552471)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top